ENDPOINTS

Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial

Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the drug for more than a year, the company said Monday. ...

Mar 10, 2025 - 12:22
 0
Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial
Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the drug for more than a year, the company said Monday. ...
Read More

Tags:

Previous Article

#ScientistAtWork 2025: <i>Nature</i> is seeking stunning photographic images tha...

Next Article

Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody

Related Posts

Arrowhead reveals small batch of open-label data for 'non-core' kidney drug

Arrowhead reveals small batch of open-label data for 'n...

Mar 10, 2025  0

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai a...

Feb 28, 2025  0

#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor data for Nectin-4 ADC

#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor...

Feb 14, 2025  0